

# Annals of the Rheumatic Diseases

Official Journal of EULAR - the European League Against Rheumatism



## 2024 RATES & DATA

REACH  
RHEUMATOLOGY  
SPECIALISTS

PUBLISHING MONTHLY

For more information on advertising,  
and to discuss your campaign  
requirements, please contact:

**JIM CUNNINGHAM**  
National Accounts Manager  
(201) 767-4170 office  
(201) 394-4426 cell  
jcunningham@cunnasso.com

Frequency  
discounts  
available!  
Ask your sales rep  
for details.

ard.bmj.com

**BMJ**

# Annals of the Rheumatic Diseases

## 2024 RATES & DATA

*Annals of the Rheumatic Diseases (ARD)* is an international, peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic diseases, and connective tissue disorders. *ARD* publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured.

*ARD* is the official journal of EULAR - the European League Against Rheumatism and all scientific delegates to the annual EULAR congress receive a complimentary 12-month subscription to the journal.

At a glance	
Year established:	1939
Impact factor:	27.4*
Rank	2/34 in Rheumatology*
Editor-in-Chief:	Professor Joseph Smolen
Online Frequency:	Continuously published

\* Source: 2022 Journal Citation Reports®, Clarivate Analytics, 2023

Digital traffic	
Global sessions*	3.8M
Global page views*	5.23M
U.S. sessions*	1.1M
U.S. page views*	1.33M
e-Newsletter recipients	4k+
Global eTOC recipients	6.2k

\* Source: Google Analytics, Aug 2022 - July 2023


Contact a sales representative for the latest figures.

# ADVERTISING OPPORTUNITIES

Print and online advertising options available, as well as tailored packages including:

- Reprints and ePrints
- Email table of content (eTOC) alerts
- e-Newsletter advertising
- Podcast
- Print advertising
- Print cover wraps and tips

ARD online offers the opportunity to target your products through geo-targeted, online advertising. There are a full range of digital opportunities available.



## DIGITAL ADVERTISING RATES

	Pixels	Rate	Specifications
Website mobile banner	320 x100	\$88 per 1,000 impressions	File type GIFs (animated preferred) and Rich Media accepted, subject to production clearance. File size up to 150k.
Website leaderboard	728 x 90	\$88 per 1,000 impressions	
Website MPU (Mid page unit)	300 x 250	\$92 per 1,000 impressions	Deadline to receive materials 5 working days prior to deployment.
eTOC alert leaderboard	320 x 100	Please contact Jim Cunningham at <a href="mailto:jcunningham@cunnasso.com">jcunningham@cunnasso.com</a> for the latest email advertising rates.	JPEG or GIF accepted  Please note: Advertisements are accepted subject to availability and BMJ approval.
eTOC alert MPU	300 x 250	Please contact Jim Cunningham at <a href="mailto:jcunningham@cunnasso.com">jcunningham@cunnasso.com</a> for the latest email advertising rates.	
e-Newsletter	600 x 90	Please contact Jim Cunningham at <a href="mailto:jcunningham@cunnasso.com">jcunningham@cunnasso.com</a> for the latest email advertising rates.	

# TARGETED SOLUTIONS

Annals of the  
**Rheumatic Diseases**  
**ARD** 2024 Rates & Data

Hurry! Limited opportunities available.

## DIGITAL ROADBLOCK PACKAGE

**Your ad here**

BMJ Journals

Subscribe Log in Basket Search

Annals of the Rheumatic Diseases

Latest content Current issue Archive Authors About Podcast

Home Online First Email alerts

Article Text

Article info

Citation Tools

Share

Responses

Article metrics

Alerts

Correspondence

Clinical evidence guidelines in systemic lupus erythematosus: reevaluation

Morton Scheinberg

Author affiliations +

<https://doi.org/10.1136/annrheumdis-2018-214357>

Request Permissions

The paper on the First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus (SLE) points to some conclusions that need to be further clarified since the bulk of evidence points to a different direction. Belimumab safety and efficacy has been well documented since its approval during the last 5 years, and in particular the skin and joint domains appear to have ...

View Full Text

**Your ad here**

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center's RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Request permissions

Copyright information: © Author(s) for their employer(s) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Read the full text or download the PDF:

Buy this article (£27.60) Subscribe Log in

eular

eular TEXTBOOKS

CONTENT

Latest content

Current issue

Lay summaries

Archive

Browse by topic

Most read articles

Responses

JOURNAL

About

Editorial board

Thank you to our reviewers

Sign up for email alerts

Subscribe

EULAR textbooks

AUTHORS

Instructions for authors

Submit an article

Editorial policies

Open Access at BMJ

BMJ Author Hub

HELP

Contact us

Reprints

Permissions

Advertising

Feedback form

This exclusive opportunity gives your ads 100% share-of-voice on the website and within the email table of content (eTOC) alerts for an entire month.

■ Banner ads

■ eTOC alerts

Frequency discounts available! Ask your sales rep for details.

**Your ad here**

Open as a webpage »

Annals of the Rheumatic Diseases

Latest articles

Correspondence response | Correspondence |

Correspondence response

- Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al  
Sofia Ramiro, Rémy Mostard, Robert BM Landewé (2020-08-19)  
[10.1136/annrheumdis-2020-218788](https://doi.org/10.1136/annrheumdis-2020-218788)
- Response to: 'Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?' by Yamashita et al  
Marie Pouletty, Glory Dingulu, Naim Ouldali et al. (2020-08-21)  
[10.1136/annrheumdis-2020-218644](https://doi.org/10.1136/annrheumdis-2020-218644)
- Response to: 'Case of postpartum axial spondyloarthritis' by Furuhashi et al  
Adel Hoballah, Cédric Lukas, Christophe Leplat et al. (2020-08-21)  
[10.1136/annrheumdis-2020-218687](https://doi.org/10.1136/annrheumdis-2020-218687)
- Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation—an open-label cohort study' by Della-Torre et al' by Cheng and Zhang  
Emanuel Della-Torre, Giovanni Landoni, Alberto Zangrillo et al. (2020-08-19)


# TARGETED SOLUTIONS

Annals of the  
**Rheumatic Diseases**

**ARD** 2024 Rates & Data

**Hurry! Limited opportunities available.**

## E-NEWSLETTER SPONSORSHIP



**Authentic,  
society-approved  
messaging**

Send new research to your audience through a monthly e-newsletter sponsorship. Content is selected by the Editorial team and sent to U.S. rheumatologists. 30% average open and email click through rate.

▪ **Annual sponsorships available**

▪ **4k+ recipients, including:**

- eTOC registrants
- Opted-in specialists

▪ **Two ad slots per e-newsletter:**

- 600 x 90: animation accepted

▪ **Twelve-month, exclusive sponsorship available**

- Please contact Jim Cunningham at [jcunningham@cunnasso.com](mailto:jcunningham@cunnasso.com) for the latest email advertising rates.

**Editor-approved  
articles**


# TARGETED SOLUTIONS

Hurry! Limited opportunities available.

Annals of the  
**Rheumatic Diseases**

**ARD** 2024 Rates & Data

## COVER WRAP SPONSORSHIP



Boost your brand's recognition with a sponsored print subscription. Each sponsored issue includes a four to six-page ad that wraps around the front and back of *ARD* and is mailed to your targeted physician list.

Cover wraps are permanently bound to the journal and garner premium exposure to your audience.

Frequency  
discounts  
available!  
Ask your sales rep  
for details.

For more information on advertising, and to discuss your campaign requirements, please contact:

**JIM CUNNINGHAM**  
National Accounts Manager  
(201) 767-4170 office  
(201) 394-4426 cell  
jcunningham@cunnasso.com